LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global stem cell therapy market to grow at a CAGR of close to 37% during the forecast period, according to their latest report.
The research study covers the present scenario and growth prospects of the global stem cell therapy market for 2017-2021. To determine the market size, the study considers revenue generated from allogenic and autogenic stem cell therapies.
| The Americas is the largest regional segment of the global stem cell therapy market, responsible for generating over 56% of the total revenue (2016 figures). The region is expected to continue market dominance through the forecast period, driven by increasing demand for stem cell therapy products and investments into R&D. |
Request a sample report: http://www.technavio.com/request-a-sample?report=55182
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Technavio analysts highlight the following three factors that are contributing to the growth of the global stem cell therapy market:
- Increase in federal funding in stem cell therapy
- Growing demand for personalized medicine
- Demand for development of effective drugs for cardiology and degenerative disorders
Increase in federal funding in stem cell therapy
Sapna Jha, one of the lead research analysts at Technavio for medical imaging research, says, “Many stem cell research institutes and small companies are involved in cutting-edge R&D and are yielding encouraging results. These institutions are witnessing an increased flow of investments from federal organizations, due to the realization of the importance of regenerative medicine.”
The US National Institute of Health, a major funding government organization invested approximately USD 1.5 billion in stem cell research projects in 2016. Similarly, several state-level organizations such as California Institute for Regenerative Medicine has contributed USD 3 billion to stem cell research in 2014. Such funding will help various research institutes to discover and develop regenerative medicines, which will boost the global regenerative medicine market enormously.
Growing demand for personalized medicine
The healthcare sector is creating a high demand for personalized medicine, which could offer game-changing opportunities for the vendors. These medicines offer treatments based on the individual characteristics, needs, and preferences, which will vastly improve the quality of healthcare. Individuals are increasingly banking their stem cells for future treatments. Research organizations are also extensively exploring ways to develop personalized treatments with stem cells, which could eventually erase the conventional medicine system and help in the effective treatment of various diseases such as diabetes and cancer.
Demand for development of effective drugs for cardiology and degenerative disorders
“There has been an increased demand to develop effective drugs for cardiology and degenerative disorders, for which there were no effective treatment plans before the advent of stem therapies. The discovery of possible cardiac stem cells uncovered new arenas to repair hearts injured due to acute myocardial infarction or coronary artery disease,” says Sapna.
Researchers are studying and developing approximately 19 product candidates for the treatment of cardiac disorders, with eight of them in Phase III, and six in Phase II. Some of the major companies involved in the development of these drugs include Shire, Athersys, Daiichi Sankyo, Mesoblast, Japan Regenerative Medicine, and Celyad. These products are expected to be launched during the forecast period and are expected to have a substantial impact on the market growth.
Browse Related Reports:
- Global Spine Biologics Market 2016-2020
- Global Transplant Diagnostics Market 2016-2020
- Global Orthobiologics Market 2016-2020
Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like cardiovascular devices, in-vitro diagnostics, and patient monitoring devices. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.
About Technavio
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users.
If you are interested in more information, please contact our media team at media@technavio.com.
